Therapy Development by Genome Editing of Hematopoietic Stem Cells

Area of Science:

• Biotechnology
• Genetics
• Hematology

Background:

• Hematopoietic stem cells (HSCs) are crucial for blood and immune system repopulation, making them key targets for cell and gene therapy.
• Advances in genome editing tools, especially CRISPR/Cas systems, have significantly transformed gene therapy development.

Purpose of the Study:

• To provide an overview of recent progress in HSC genome editing for inherited disorders.
• To summarize key findings from preclinical and clinical studies of HSC-based therapies.
• To discuss technical challenges and future advances for clinical translation.

Main Methods:

• Review of recent preclinical and clinical studies on HSC genome editing.
• Focus on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) and derived editing systems.
• Analysis of efficiency, precision, tolerability, distribution, and affordability of HSC therapies.

Main Results:

• CRISPR/Cas and derived systems offer versatile genomic editing for gene disruption, correction, or insertion.
• HSC genome editing has accelerated the development of potential curative therapies for rare inherited diseases.
• Significant progress has been made in preclinical and clinical studies, broadening therapeutic targets.

Conclusions:

• HSC genome editing holds immense promise for treating inherited disorders.
• Addressing technical hurdles in efficiency, precision, and accessibility is vital for routine clinical translation.
• Future advances may enable broader application of HSC-based genome editing beyond common disorders.